Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

25 Sept 2018

Abstract excerpt

Philadelphia chromosome, reciprocal translocation between chromosome 9 and 22, leading to a constitutively active fusion protein BCR-ABL1 is the common feature among Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) and chronic myeloid leukemia (CML). The discovery of tyrosine kinase inhibitors (TKIs) has led to significant improvement in the treatment of CML and Ph+ ALL. Ponatinib is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30251548
DOI: 10.2217/fon-2018-0371

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ponatinib in the Treatment of Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaPMID 30251548Read ↗

Ponatinib in refractory Philadelphia chromosome-positive leukemias.Semantic proximity Read ↗

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasSemantic proximity Read ↗

Ponatinib in the therapy of chronic myeloid leukemia.Semantic proximity Read ↗

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – final 6-year results from a Belgian registrySemantic proximity Read ↗

Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – Final 6-year results from a Belgian registrySemantic proximity Read ↗

Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE TrialSemantic proximity Read ↗

New and established tyrosine kinase inhibitors for chronic myeloid leukemiaSemantic proximity Read ↗

Resistant mutations in CML and Ph+ALL &ndash; role of ponatinibSemantic proximity Read ↗

Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Semantic proximity Read ↗

Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?Semantic proximity Read ↗

Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALLSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.